Upon initiation or discontinuation of guselkumab in patients who're receiving concomitant CYP450 substrates, especially All those with a slender therapeutic index, consider monitoring for therapeutic effect. Con el fin de protegerlos de una intoxicación, siempre use tapaderas de seguri